Corrigendum to “Novel oral nano-hepatic targeted anti-PCSK9 in hypercholesterolemia” [Nanomedicine 40 (2022 Feb); 102480. doi: 10.1016/j.nano.2021.102480]

IF 4.7 4区医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Nanomedicine: Nanotechnology, Biology and Medicine Pub Date : 2022-11-01 DOI:10.1016/j.nano.2022.102602

Taher A. Salaheldin PhD , Kavitha Godugu PhD , Dhruba J. Bharali PhD , Kazutoshi Fujioka PhD , Nabil Elshourbagy PhD, FAHA , Shaker A. Mousa PhD, MBA, FACC, FACB

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

“新型口服纳米肝靶向抗pcsk9治疗高胆固醇血症”的勘误表[纳米医学40(2022年2月);102480. doi: 10.1016 / j.nano.2021.102480]

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nanomedicine: Nanotechnology, Biology and Medicine 医学-纳米科技

CiteScore

8.10

自引率

3.60%

发文量

104

审稿时长

4.6 months

期刊介绍： Nanomedicine: Nanotechnology, Biology and Medicine (NBM) is an international, peer-reviewed journal presenting novel, significant, and interdisciplinary theoretical and experimental results related to nanoscience and nanotechnology in the life and health sciences. Content includes basic, translational, and clinical research addressing diagnosis, treatment, monitoring, prediction, and prevention of diseases.